New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback